Hypoxia caused by Sorafenib, on the other hand, can boost the accumulation of HIF-1α and HIF-2α in the nucleus, hence accelerating oncogene transcription and enhancing the tolerance of hepatoma cells to Sorafenib (Méndez-Blanco et al., 2018). Here, HIF1A is linked to hepatocellular carcinoma.